The Oncology Institute raises $16.5M via private placement and exchanges $4.1M notes

Oncology Institute, Inc.

Gross proceeds of ~$16.5M from issuing 12.0M common shares, pre-funded warrants for 2.9M shares, and common warrants for 7.4M shares.
Deerfield exchanges ~$4.1M senior secured convertible notes for 37,233 preferred shares (convertible into 3.7M common) and warrants for 1.9M shares.
Common warrants exercisable at $1.1980/share for 5 years; pre-funded warrants at $0.0001/share.
Proceeds to support organic growth and working capital; closing expected March 26, 2025.

item 1.01 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Oncology Institute, Inc.: Increased the number of shares of Series A Convertible Preferred Stock from unspecified prior amount to 213,000 via an amendment to the Certificate of Designation, effective March 24, 2025, and also filed a Certificate of Correction to correct an administrative error (effective 2025-03-24).

Change: charter amendment
Effective: 2025-03-24

Exact text from the filing

On March 24, 2025, the Company filed an amendment to Certificate of Designation of Preferences, Rights and Limitations of Series A Common Stock Equivalent Convertible Preferred Stock (the “ Certificate of Designation ” and such amendment, the “Amendment to Certificate of Designation ”) with the Secretary of State of the State of Delaware in connection with the Exchange , effective on March 24, 2025.

View on SEC.gov

74 governance changes filed in the last 30 days. Browse all governance changes →

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001079973-25-000460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.